1 / 43

BPH management . Overview of treatment options

BPH management . Overview of treatment options. Antonio Alcaraz. EAU guidelines. EAU: International guidelines recommend treatment algorithms to guide medical treatment choices according to patient profile.

bronner
Télécharger la présentation

BPH management . Overview of treatment options

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BPH management. Overview of treatmentoptions Antonio Alcaraz

  2. EAUguidelines EAU: International guidelines recommend treatment algorithms to guide medical treatment choices according to patient profile Oelke M et al. EurUrol 2013. http://dx.doi.org/10.1016/j.eururo.2013.03.004 Accessed on 8th April 2013. 2 Prescribing information can be found at the end of the presentation

  3. Men >40 yo Histological BPH Prostatic growth ` UT obstruction LUTS Medical therapy in BPH evolution.

  4. BPH prevalence according definition and age Prevalence (%) 100 80 60 40 20 0 40–49 50–59 60–69 70–79 Edad (años) Pathological prevalence(n=1057) DRE(n=6975) History and physical exam(n=1057) Symptoms, IPSS (Scotland, n=699) Symptoms and flujometria (Rochester, n=2115) DRE (n=1057) Combined medical therapy in BPH

  5. URINARY SYMPTOMS PREVALENCE IN MEN N=5460 VOIDING 25.7% FILLING 49.7% NO LUTS LUTS POST-VOIDING 16.5% 6 OUT OF10 MEN

  6. Management options of LUTS • Prostate • Alfa blockers • Symptomatic control • 5 alfareductase inhibitors • Disease modification • Long term Symptomatic control • Surgical management • Symptomatic and modification of natural history of the disease • Bladder • Antimuscarinics • Symptomatic control

  7. Evolution of BPH therapy. 90s • Finasteride approved in 1992 • Terasozina approved in 1993 • Doxasozina approved in 1995 • Tamsulosina approved in 1997 • Dutasteride 1998

  8. Medical therapy and hospital admission Drug Therapy for BPH and Hospital Admission Souverein et al: Eur Urology 43:528, 2003

  9. ‘Tailor’-made treatment of BPH Drug efficacy Prostate volume PSA Sexual dysfunction Sexually active Metabolic syndrome Impacton BPH progression Risk ofside effects

  10. EAUguidelines EAU guidelines: α-blockers/PDE5-Is should be offered to men with moderate-to-severe LUTS Storage symptoms predominant? No Prostate volume >40 ml? No Yes Long-term treatment? No Education + Lifestyle Advice with or withoutα2-blocker/PDE5-I Prostate size does not affect α1-blocker efficacy in studies with follow-up periods of <1 year but patients with a prostate volume of <40 mL seem to have better efficacy compared with those with larger glands in the longer term and is similar across age groups α1-blockers do not reduce prostate size and do not prevent AUR in long-term studies Oelke M et al. Eur Urol 2013. http://dx.doi.org/10.1016/j.eururo.2013.03.004 Accessed on 8th April 2013. Prescribing information can be found at the end of the presentation

  11. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction (BPO) * • EAU guidelines recommend alpha-1 blockers to be offered to men with moderate-to-severe LUTS based on level 1A evidence. • α1-blockers are often considered the first-line drug treatment of male LUTS because of their rapid onset of action, good efficacy, as well as the low rate and severity of adverse events. *we mentioned here the section related to Alpha-blocker only M. Oelke et al, EUROPEAN UROLOGY 6 4 ( 2 0 1 3 ) 1 1 8 – 1 4 0

  12. α-blockers pharmacological selectivity

  13. a1-adrenoceptor antagonists (a1-blockers) • Efficacy • Controlled studies have shown that α1-blockers typically reduce the International Prostate Symptom Score (IPSS), after a run-in period, by approximately 30-40% and increase the maximum urinary flow rate (Qmax) by approximately 20-25%. • significant efficacy of α1-blockers over placebo was demonstrated within hours to days and maintained over at least 4 years. Alf 053 DA NE (NE) 09-13 M. Oelke et al, EUROPEAN UROLOGY 6 4 ( 2 0 1 3 ) 1 1 8 – 1 4 0

  14. ‘Tailor’-made treatment of BPH Risk ofside effects

  15. AUA meta-analysis: dizziness with medical therapies ALFUZOSIN Doxazosin TAMSULOSIN* Terazosin FINASTERIDE Alfuzosin/Finasteride Doxazosin/Finasteride Terazosin/Finasteride PLACEBO 0% 10% 20% 30% Estimated Occurrence Rate with 95% CI *Tamsulosin 0.4mg to 0.8mg AUA Guidelines on Management of BPH J. Urol. 2003, 170, 530-547

  16. AUA meta-analysis: symptomatic postural hypotension ALFUZOSIN Doxazosin TAMSULOSIN* Terazosin FINASTERIDE Alfuzosin/Finasteride Doxazosin/Finasteride Terazosin/Finasteride PLACEBO 0% 10% 20% 30% Estimated Occurrence Rate with 95% CI *Tamsulosin 0.4mg to 0.8mg AUA Guidelines on Management of BPH J. Urol. 2003, 170, 530-547

  17. AUA meta-analysis: headache with medical therapies ALFUZOSIN Doxazosin TAMSULOSIN* Terazosin FINASTERIDE Alfuzosin/Finasteride Doxazosin/Finasteride Terazosin/Finasteride PLACEBO 0% 10% 20% 30% Estimated Occurrence Rate with 95% CI *Tamsulosin 0.4mg to 0.8mg AUA Guidelines on Management of BPH J. Urol. 2003, 170, 530-547

  18. ALFUZOSIN Doxazosin TAMSULOSIN Terazosin FINASTERIDE Alfuzosin/Finasteride Doxazosin/Finasteride Terazosin/Finasteride PLACEBO Estimated Occurrence Rate with 95% CI 0% 10% 20% 30% AUA meta-analysis: ejaculatory dysfunction with medical therapies AUA Guidelines on Management of BPH J. Urol. 2003, 170, 530-547

  19. ‘Tailor’-made treatment of BPH Sexually active Sexual dysfunction Co-prescription with PDE5 inhibitors? Deleterious effects on ejaculation? Improving erection and ejaculation?

  20. Multinational Survey of Ageing Male (MSAM-7) • Patients: • 12,815 patients representative of men 50–80 years in 7 countries (US, UK, F, Ge, I, Sp, NL) • Methods: postal questionnaire • Demographic characteristics • IPSS • DAN-PSSsex, IIEF • Co-morbidity Rosen et al. Eur Urol 2003; 44: 637- 49

  21. MSAM-7: ED, LUTS & Age Average IIEF* LUTS Age (years) *International Index of Erectile Function (IIEF); 26 to 30 = normal erectile function; 22 to 25 = mild ED;17 to 21 = mild-to-moderate ED;11 to 16 = moderate ED; ≤10 = severe ED. Rosen R et al. Eur Urol. 2003;44:637-649

  22. MSAM-7: Conclusions • BPH/LUTS, ED and EjD are common problems in aging men • Presence and severity of BPH/LUTS is a major, independent risk factor for sexual dysfunction • Sexual function should be considered in the initial evaluation of men with BPH/LUTS Rosen et al. Eur Urol 2003; 44: 637-49

  23. Is ejaculatory dysfunction (EjD)observed with tamsulosindue to retrogradeejaculation?

  24. ABEJAC study Change in ejaculate volume Change in urine sperm concentration p=ns *Tam vs Pbo, p<0.001 Tam vs Alf, p<0.001 +1.7 +0.4 +0.3 +1.4 +1.2 -2.4 * Mean ±sd value at baseline 48 ± 0.5 million/ml Mean ±sd value at baseline 3.4 ± 1.4 ml Tamsulosin 0.8mg OD Alfuzosin 10mg OD Placebo Intent to treat population Hellstrom W. J. Urol. 2006, 176, 1529-1533

  25. ABEJAC Study Complete unejaculation 35.4% Percentage of patients 0% 0% Tamsulosin 0.8mg OD Alfuzosin 10mg OD Placebo Among completers (n=48) Hellstrom,WJG. J Urol. 2006, 176, 1529-33

  26. EAUguidelines EAU guidelines: α-blockers/PDE5-Is should be offered to men with moderate-to-severe LUTS Storage symptoms predominant? No Prostate volume >40 ml? No Yes Long-term treatment? No Education + Lifestyle Advice with or withoutα2-blocker/PDE5-I Prostate size does not affect α1-blocker efficacy in studies with follow-up periods of <1 year but patients with a prostate volume of <40 mL seem to have better efficacy compared with those with larger glands in the longer term and is similar across age groups α1-blockers do not reduce prostate size and do not prevent AUR in long-term studies Oelke M et al. Eur Urol 2013. http://dx.doi.org/10.1016/j.eururo.2013.03.004 Accessed on 8th April 2013. Prescribing information can be found at the end of the presentation

  27. Background • LUTS and sexual dysfunction are strongly associated1-2 • The co-prescription of drugs treating LUTS and ED is increasing • Both PDE5 inhibitors and α1-blockers may have an impact on blood pressure which differs from one drug to another in a same class 1Rosen et al. Eur.Urol. 2003; 44: 637-649 2Vallancien et al. J.Urol. 2003; 169: 2257-2261

  28. PDE5i and BPH Egerdie RB et al. J Sex MDE 2012;9:271–281 Porst et al. EurUrol2011;60(5):1105-13. Roehrborn et al. J Urol 2008;180(4):1228-34. Oelke M et al. Eur Urol 2012;61: 917- 925

  29. ConfirmatorystudyTadalafil 5 mg: Cambio mDEio mínimo en el IPSS total ** * ** Basal Semana 1a Semana 4 Semana 8 Semana 12 *p<0,05, **p<0,01, Porst et al. Eur Urol 2011;60(5):1105-13.

  30. Tadalafil: 12 monthseffect IPSS per visit1,2 IPSS total media Change at theend of thetreatment (UOR, n = 416)mean (DS) Placebo → 5 mg -2,2 (5,3) 0,2 (5,4) 5 mg → 5 mg Periodo doble ciego controladocon placebo Extensión abierta con Tadalafilo 5 mg diario Semana 8 10 11 3 9 12 Visita 6 Thelongtreatmentwithtadalafilo 5mg dailywereeffective in maintainthereduction of LUTS/BPH. This trial of 12 monthswastheampliation of thestudylookingfor doses. Donatucci et al. BJU Int 2011;107(7):1110-6.

  31. Can α1-Blockers and PDE5-Inhibitorsbe Safely Combined?

  32. Interaction Studies • 3 placebo-controlled, randomized, cross-over studies assessed the hemodynamic interactionof Tadalafil 20mg with α1-blockers: • Doxazosin 0.8mg (18 healthy volunteers)1 • Tamsulosin 0.4mg (18 healthy volunteers)1 • Alfuzosin 10mg OD (18 healthy volunteers)2 • Endpoints: • Maximal post-baseline drop in standing and supine SBP and DBP (primary) • Outliers (secondary): SBP<85 mmHg, DBP<45 mmHg, drop in SBP vs baseline >30 mmHg, drop in DBP vs baseline >20 mmHg 1Kloner RA et al. J Urol. 2004;172:1935-19402Giuliano F. et al. Urology 2006 67, 1199-1204 .

  33. Difference vs Placebo in Maximum Dropin Supine & Standing Blood Pressure Supine Standing SBP DBP DBP SBP * * * *statistically significant(95% CI did not contain 0) * 1Kloner RA et al. J Urol. 2004;172:1935-19402Giuliano F. et al. Urology 2006 67, 1199-1204 .

  34. Conclusions • Tadalafil augments the hypotensive effect of doxazosin but shows marginal hemodynamic interaction with alfuzosin and tamsulosin

  35. EAUguidelines EAU guidelines: α-blockers/PDE5-Isshould be offered to men with moderate-to-severe LUTS Storage symptoms predominant? No Prostate volume >40 ml? No Yes Long-term treatment? No Education + Lifestyle Advice with or withoutα2-blocker/PDE5-I Prostatesizedoesnotaffect α1-blocker efficacy in studies with follow-up periods of <1 year but patients with a prostate volume of <40 mL seem to have better efficacy compared with those with larger glands in the longer term and is similar across age groups α1-blockers do not reduce prostate size and do not prevent AUR in long-termstudies Oelke M et al. Eur Urol 2013. http://dx.doi.org/10.1016/j.eururo.2013.03.004 Accessed on 8th April 2013.

  36. 2000s. MTOPS study (Medical Therapy of Prostatic Symptoms) 3047 PATIENTS Finasteride 5mg Doxazosin 4-8mg Combined therapy Placebo Follow-up: 4.5 years Age >50 IPSS 8-30 Q max 8-15 ml/sec No requirements of prostate volume No requirements regarding minimum PSA McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med. 2003;349:2387.

  37. MTOPS – invasive therapy needed Placebo Doxazosin (p=ns) Finasteride (p<0.001) Combo (p<0.001) Incidence (%) 10 8 6 4 2 0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 Años McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med. 2003;349:2387. McConnell et al. NEJM 2003

  38. MTOPS – Accumulatedindex of progression 67% McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med. 2003;349:2387. McConnell JD, et al.  MTOPS. N Engl J Med. 2003

  39. CombAT at 4 years – Incidence of AUR or surgery for BPH

  40. High prostate volume, PSA. High PVR and low Qmax • Marked intravesical protrusion. • Deterioration with medical therapy.

  41. There are to identify before its happen.

More Related